Feb 18 (Reuters) - Solid Biosciences Inc SLDB.O:
SOLID BIOSCIENCES INC: SGT-003 HAS BEEN WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS OBSERVED
SOLID BIOSCIENCES INC - AVERAGE MICRODYSTROPHIN EXPRESSION OF 110% OBSERVED IN PHASE 1/2 TRIAL OF SGT-003
SOLID BIOSCIENCES - PLANS TO REQUEST FDA MEETING FOR ACCELERATED APPROVAL PATHWAY IN MID-2025 FOR SGT-003
Source text: ID:nGNX47H0x5
Further company coverage: SLDB.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.